Latest news

Thumbnail image for SBRI awards £8.7m to primary care projects

SBRI awards £8.7m to primary care projects

Ten UK companies are to benefit from a share of £8.7 million provided by SBRI Healthcare to drive development of new technologies that could revolutionise the delivery of general practice.

20th February 2018

Thumbnail image for Janssen’s psoriasis biologic Tremfya shows long-term effect

Janssen’s psoriasis biologic Tremfya shows long-term effect

Top-line trial data unveiled by Janssen at the 2018 American Academy of Dermatology (AAD) Annual Meeting over the weekend indicate that the benefit of Tremfya in patients with severe plaque psoriasis is maintained in the long-term.

19th February 2018

Thumbnail image for Manchester CRN gets ‘Premier Site’ status from Sanofi

Manchester CRN gets ‘Premier Site’ status from Sanofi

French drugmaker Sanofi has named NIHR Clinical Research Network Greater Manchester as its first UK Premier Site, marking a “landmark” clinical research partnership that will help accelerate R&D to address the medical need of patients.

19th February 2018

Thumbnail image for US clears AZ’ Imfinzi for lung cancer

US clears AZ’ Imfinzi for lung cancer

US regulators have expanded the scope of AstraZeneca/MedImmune’s immunotherapy Imfinzi to include patients with a certain form of lung cancer.

19th February 2018

Thumbnail image for Tetraphase stock plummets on antibiotic failure

Tetraphase stock plummets on antibiotic failure

Tetraphase Pharmaceuticals saw its stock plummet after revealing that a Phase III study of its experimental antibiotic eravacycline missed key targets in a late stage trial.

15th February 2018

Thumbnail image for Shire’s SHP647 bags another orphan badge

Shire’s SHP647 bags another orphan badge

US regulators have awarded orphan drug status to Shire's investigational therapy, SHP647, for the treatment of paediatric patients with moderately to severely active Crohn's disease.

15th February 2018

Thumbnail image for BMS, Nektar to jointly develop, commercialise immunotherapy combo

BMS, Nektar to jointly develop, commercialise immunotherapy combo

Bristol-Myers Squibb and Nektar Therapeutics have signed a deal to develop and commercialise the latter’s lead immuno-oncology programme, NKTR-214, in combination with other anticancer therapies, on the back of the success of a previous clinical trials pact.

15th February 2018

Previous  --   10 11 12 13 14 15 16 17 18 19   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download